SEC Form 4 · accession 0000899243-19-001732
ARVINAS, INC. · ARVN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John G Houston
Officer — President and CEO · Director
Period of report
Jan 18, 2019
Accepted (ET)
Jan 23, 2019 · 5:19 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001655759
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $16.00 | Jan 18, 2019 | A | 13,360 | A | Jan 18, 2019 | Sep 25, 2028 | Common Stock | 13,360 | 13,360 | D |
Explanation of responses
- F1On September 26, 2018, the reporting person was granted an option to purchase 13,360 shares of common stock, which was reported on Form 4 filed September 28, 2018. The option vests upon achievement of a regulatory milestone for the Issuer's androgen receptor program. On January 18, 2019, the compensation committee of the Issuer determined that the regulatory milestone was met, resulting in vesting of the option in full.